Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab

Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate du...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2007-02, Vol.56 (2), p.217-221
Hauptverfasser:	Hassan, Akmal S., MD, Kaelin, Ursula, MD, Braathen, Lasse Roger, MD, PhD, Yawalkar, Nikhil, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Allergic diseases Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Biological and medical sciences CD11 Antigens - immunology Dermatitis, Atopic - drug therapy Dermatitis, Atopic - immunology Dermatitis, Atopic - metabolism Dermatitis, Atopic - pathology Dermatology Humans Immunohistochemistry Immunopathology Macrophages - immunology Male Medical sciences Skin - immunology Skin - pathology Skin allergic diseases. Stinging insect allergies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of widespread moderate to severe atopic eczema remains a challenge. The therapeutic efficacy and modifications of the immune response during treatment of atopic eczema with efalizumab are so far unknown. We hereby report the clinical findings and characterize the inflammatory infiltrate during treatment of severe recalcitrant atopic eczema with efalizumab.
ISSN:	0190-9622 1097-6787
DOI:	10.1016/j.jaad.2006.08.025